Claims

15

25

 A peptide having an amino acid sequence of Formula I (SEQ ID NO: 1): X₁FGAPX₂ X₃ in which

 X_1 , is selected from Aspartic acid and a derivative thereof selected from acylated and alkylated Aspartic acid;

 X_2 is Leucine or when X_3 is absent, X_2 is selected from Leucine and amidated Leucine:

 X_3 is absent or selected from Aspartic acid and amidated Aspartic acid; as well as salt and any derivative or analogue thereof.

2. A peptide according to claim1 wherein X1 and X3 are Aspartic acid.

3. A peptide according to claims 1 or 2 wherein X₃ is absent.

4. A peptide according to any of the preceding claims of the Formula II below:

Formula II

wherein R^1 is selected from H, C_2 -C₆ acyl and C_1 -C₆ alkyl; R^2 is selected from OH and NR^3R^4 , wherein R^3 and R^4 are independently selected from H and C_1 -C₆ alkyl and R^5 , R^6 , R^7 , R^8 and R^9 are independently selected from H and C_1 -C₆ alkyl.

5. A peptide according to claim 4 wherein R^1 is selected from H and C_2 - C_6 acyl and R^2 is selected from OH and NH₂.

10

- 6. A peptide according to claim 4 wherein R1 is H and R2 is OH.
- 7. A peptide according to claim 1 of the Formula III below:

Formula III

wherein R^1 is selected from H, C_2 - C_6 acyl and C_1 - C_6 alkyl; R^2 is selected from OH and NR^3R^4 , wherein R^3 and R^4 are independently selected from H and C_1 - C_6 alkyl and R^5 , R^6 , R^7 and R^8 are independently selected from H and C_1 - C_6 alkyl.

- 8. A peptide according to claim 7 wherein R^1 is selected from H and C_2 - C_6 acyl and R^2 is selected from OH and NH₂.
- 9. A peptide according to claims 7 or 8 wherein R¹ is acetyl and R² is NH₂.
 - 10. A peptide according to any of the preceding claims wherein R^5 , R^6 , R^7 and R^8 are H.
- 11. A peptide according to any preceding claims selected from the following group: SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4.
 - 12. A compound according to any of the preceding claims for use as a medicament.
- 13. Use of a peptide according to claims 1 to 11 for the preparation of a medicament for the treatment or prevention of an amyloidosis disorder related to IAPP.

WO 2004/083243 PCT/EP2004/050320

23

14. Use according to claim 13 wherein the amyloidosis disorder is a diabetic disorder.

- 15. Use according to claim 14 wherein the diabetic condition is Type II diabetes.
- 16. Use according to claim 14 wherein the diabetic condition is post-transplantation Type I diabetes.
- 17. A pharmaceutical composition comprising a compound according to claims 1 to11 as active ingredient and a pharmaceutically acceptable excipient or carrier.
 - 18. A method of treating or preventing diabetic disorders by administering an effective amount of any of the peptides or compounds of claims 1 to 11 to a subject in the need thereof.

19. A method according to claim 18, in which the subject is human.

10

15